EA201992584A1 - NEW MAP4K1 INHIBITORS - Google Patents

NEW MAP4K1 INHIBITORS

Info

Publication number
EA201992584A1
EA201992584A1 EA201992584A EA201992584A EA201992584A1 EA 201992584 A1 EA201992584 A1 EA 201992584A1 EA 201992584 A EA201992584 A EA 201992584A EA 201992584 A EA201992584 A EA 201992584A EA 201992584 A1 EA201992584 A1 EA 201992584A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
inhibitors
new
disorders
map4k1
Prior art date
Application number
EA201992584A
Other languages
Russian (ru)
Inventor
Винод Пейтел
Венкатешвар Редди
Лаксмикант Атмарам Гхарат
Сачин Сундарлал Чаудхари
Санджиб Дас
Ранганадх Велгалети
Дайси Маниш Шах
Малини Баджпай
Original Assignee
Икнос Сайенсиз Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Икнос Сайенсиз Са filed Critical Икнос Сайенсиз Са
Publication of EA201992584A1 publication Critical patent/EA201992584A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Изобретение относится к новым ингибиторам MAP4K1 (HPK1), подходящим для лечения заболеваний или нарушений, характеризующихся дисрегуляцией путей сигнальной трансдукции, связанных с активацией MAPK, включая гиперпролиферативные заболевания, заболевания, связанные с дисфункцией иммунной системы, воспалительные нарушения, неврологические заболевания и сердечно-сосудистые заболевания. Изобретение дополнительно относится к фармацевтическим композициям, содержащим указанные ингибиторы, и к способам лечения указанных заболеваний и нарушений. Ингибиторы имеют формулу (I), где A, D, E, F, R, R, R, Z, кольцо Q, n, x и y такие, как определено в заявке.The invention relates to new MAP4K1 (HPK1) inhibitors suitable for the treatment of diseases or disorders characterized by dysregulation of signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases associated with immune system dysfunction, inflammatory disorders, neurological diseases and cardiovascular diseases . The invention further relates to pharmaceutical compositions containing said inhibitors, and to methods of treating said diseases and disorders. Inhibitors have the formula (I), where A, D, E, F, R, R, R, Z, ring Q, n, x and y are as defined in the application.

EA201992584A 2017-05-26 2018-05-28 NEW MAP4K1 INHIBITORS EA201992584A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511455P 2017-05-26 2017-05-26
US201762544531P 2017-08-11 2017-08-11
PCT/EP2018/063957 WO2018215668A1 (en) 2017-05-26 2018-05-28 Novel inhibitors of map4k1

Publications (1)

Publication Number Publication Date
EA201992584A1 true EA201992584A1 (en) 2020-06-18

Family

ID=62492619

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992584A EA201992584A1 (en) 2017-05-26 2018-05-28 NEW MAP4K1 INHIBITORS

Country Status (10)

Country Link
EP (1) EP3630778A1 (en)
JP (1) JP2021506735A (en)
KR (1) KR20200011965A (en)
CN (1) CN112601752A (en)
AU (1) AU2018272986A1 (en)
CA (1) CA3064975A1 (en)
EA (1) EA201992584A1 (en)
IL (1) IL270844A (en)
MX (1) MX2019013922A (en)
WO (1) WO2018215668A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP3894406A1 (en) 2018-12-11 2021-10-20 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
US20220169644A1 (en) 2019-03-26 2022-06-02 Janssen Pharmaceutica Nv Bicyclic hpk1 inhibitors
WO2020193511A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Hpk1 inhibitors
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US20230089368A1 (en) * 2019-07-19 2023-03-23 Anagenesis Biotechnologies S.A.S. Polyaromatic urea derivatives and their use in the treatment of muscle diseases
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
BR112023000592A2 (en) 2020-07-15 2023-01-31 Chiesi Farm Spa PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS
CN112225748B (en) * 2020-10-20 2021-11-30 四川大学华西医院 Small molecule compound with FLT3 kinase inhibitory activity and application thereof
CN114539065B (en) * 2020-11-25 2023-07-25 帕潘纳(北京)科技有限公司 Method for preparing 4-nitro-2-trifluoromethyl acetophenone
US20240116948A1 (en) 2020-12-23 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
EP4029501A1 (en) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells
WO2022167627A1 (en) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Map4k1 inhibitors
KR20230175222A (en) 2021-04-05 2023-12-29 할리아 테라퓨틱스, 인코포레이티드 NEK7 inhibitor
WO2022226182A1 (en) 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Nek7 inhibitors
CN113603635B (en) * 2021-10-08 2021-12-24 湖南速博生物技术有限公司 Method for hydrolyzing and decarboxylating aromatic dicarboxylic acid ester
EP4289427A1 (en) * 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular.
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors
CN117049938A (en) * 2023-06-20 2023-11-14 山东轩德医药科技有限公司 Preparation method of 6-bromo-2, 3-difluorotoluene

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (en) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
WO2011017142A1 (en) * 2009-08-06 2011-02-10 Merck Patent Gmbh Novel bicyclic urea compounds
CN103717600B (en) * 2011-08-10 2016-06-22 默克专利股份公司 Pyridopyrimidine derivatives
TWI520962B (en) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives

Also Published As

Publication number Publication date
WO2018215668A1 (en) 2018-11-29
IL270844A (en) 2020-01-30
AU2018272986A1 (en) 2019-12-12
CA3064975A1 (en) 2018-11-29
KR20200011965A (en) 2020-02-04
CN112601752A (en) 2021-04-02
JP2021506735A (en) 2021-02-22
MX2019013922A (en) 2020-08-17
EP3630778A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
EA201992584A1 (en) NEW MAP4K1 INHIBITORS
EA201990912A1 (en) ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS
EA201990019A1 (en) COMPOUNDS AND COMPOSITIONS FOR SUSPENSION OF SHP2 ACTIVITY
EA201991198A1 (en) AMINOTIAZOLE COMPOUNDS AS c-Kit INHIBITORS
EA201891910A1 (en) PAD4 HETEROARYLINARY INHIBITORS
EA201890338A1 (en) OXADIAZOLIC DERIVATIVES SUITABLE AS HDAC INHIBITORS
EA201991197A1 (en) BENZIMIDAZOLE COMPOUNDS AS c-Kit INHIBITORS
EA201691442A1 (en) N-AZASPROCYCLOALKAN-SUBSTITUTED N-HETEROARRYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING SHP2 ACTIVITY
EA201792047A1 (en) NEW CONNECTIONS
EA201891974A1 (en) INHIBITORS OF BINDING WDR5 PROTEIN WITH PROTEINS
EA202091484A1 (en) 4-AZAINDOL CONNECTIONS
EA201590850A1 (en) TRICYCLIC CONDENSED TIOPHENE DERIVATIVES AS INHIBITORS JAK
EA201390711A1 (en) HYDROXYAMIDE COMPOUNDS OF Pyrimidine As Inhibitors of Protein Deacetylases and Methods for Their Use
EA202091709A1 (en) DNA PC INHIBITORS
EA201790764A1 (en) NEW CARBON ACID CONNECTIONS SUITABLE FOR INHIBITING MICROSOMAL PROSTAGLANDIN-E2-SYNTHASE 1
EA201591746A1 (en) METHODS AND COMPOSITIONS FOR INHIBITING BRODOMODEN-CONTAINING PROTEINS
EA201790108A1 (en) HETEROARRYL COMPOUNDS SUITABLE AS AN INHIBITOR SUMO-ACTIVATING ENZYME
EA201891539A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201490042A1 (en) AZETIDINYL-PHENYL-, PYRIDYL- OR PYRAZYNYLKARBOXAMID DERIVATIVES AS INHIBITORS
EA201391329A1 (en) MODULATION OF THE EXPRESSION OF THE SIGNAL TRANSDUCER AND TRANSCRIPTION 3 ACTIVATOR
EA201691447A1 (en) 2-AMINO-3,5,5-TRIFTOR-3,4,5,6-TETRAGIDROPYRIDINES AS BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EA201490030A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA201391230A1 (en) COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS
EA201892008A1 (en) CONNECTIONS AND METHODS OF TREATMENT OF NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS
EA201891251A1 (en) PAD4 BICYCLIC INHIBITORS